Abstract
Ischemic stroke is a health problem that causes death and neurovascular disability worldwide. The inflammatory response due to infection can increase ischemic stroke and increase brain damage through changes in blood pressure, coagulation, immune response, and endothelial function. This study aims to evaluate the rationality of antibiotic use on clinical outcomes in ischemic stroke patients. This study used a cross-sectional design. Retrospective data were taken from the medical records of Jayapura Regional Hospital for the period January 1, 2023, to May 31, 2025. The study subjects were all patients who suffered ischemic stroke and received antibiotics. Evaluation of the rationality of antibiotic use used the Gyssens method. The clinical outcomes observed were whether the patient's condition improved or not in one of the patient's clinical improvement parameters, from the patient's vital signs and symptom improvement within 3-5 days of antibiotic administration. A total of 50 patients met the study inclusion criteria. Patients in this study were mostly found to be aged > 55 years (52%) and male (56%). Fifteen patients (50%) received third-generation cephalosporin antibiotics (ceftriaxone). Based on the Gyssens method assessment, 61 antibiotic regimens were rational or appropriate. Based on the chi-square test, there was a relationship between rational antibiotic use and clinical outcomes, with a p-value of 0.042 <0.05. Rational antibiotic use can improve clinical outcomes in ischemic stroke patients by 3.081 times greater than irrational antibiotic use. Pharmacists can play an important role in monitoring empirical antibiotics to prevent antibiotic resistance in patients with post-ischemic stroke infections.
Recommended Citation
Mende, Juniarto; Maturbongs, Graciano A.; and Mbulang, Yohana K. A.
(2026)
"Evaluation of Antibiotic Use Using the Gyssens Method on Clinical Outcomes in Ischemic Stroke Patients,"
Pharmacology and Clinical Pharmacy Research: Vol. 11:
Iss.
2, Article 3.
Available at:
https://journal.unpad.ac.id/pcpr/vol11/iss2/3
Page
103
Included in
Medical Pharmacology Commons, Other Pharmacology, Toxicology and Environmental Health Commons, Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy and Regulation Commons




